Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Income from Continuing Operations (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Income from Continuing Operations readings, the most recent being 23221000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 134.55% to 23221000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 95857000.0 through Dec 2025, down 61155.41% year-over-year, with the annual reading at 95857000.0 for FY2025, 61155.41% down from the prior year.
  • Income from Continuing Operations hit 23221000.0 in Q4 2025 for Terns Pharmaceuticals, up from 24635000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 67211000.0 in Q4 2024 and bottomed at 29767000.0 in Q3 2023.
  • Average Income from Continuing Operations over 5 years is 12330500.0, with a median of 19467000.0 recorded in 2023.
  • The largest annual shift saw Income from Continuing Operations soared 420.23% in 2021 before it crashed 144.48% in 2022.
  • Terns Pharmaceuticals' Income from Continuing Operations stood at 35574000.0 in 2021, then crashed by 144.48% to 15822000.0 in 2022, then crashed by 32.97% to 21038000.0 in 2023, then soared by 419.47% to 67211000.0 in 2024, then plummeted by 134.55% to 23221000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Income from Continuing Operations are 23221000.0 (Q4 2025), 24635000.0 (Q3 2025), and 24093000.0 (Q2 2025).